×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Relyvrio (Sodium Phenylbutyrate/Taurursodiol) for ALS
therapeutic
1,397 words
KG: ent-dise-93f3d65f
2026-03-22
kind:therapeutic
section:therapeutics
state:published
Contents
Relyvrio (Sodium Phenylbutyrate/Taurursodiol) for ALS
💊
Therapeutic Info
Name
Relyvrio (Sodium Phenylbutyrate/Taurursodiol) for ALS
Summary
Page for Relyvrio (Sodium Phenylbutyrate/Taurursodiol) for ALS
Knowledge Graph
Related Hypotheses (30)
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.56
SASP-Mediated Complement Cascade Amplification
Score: 0.70
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Transcriptional Autophagy-Lysosome Coupling
Score: 0.66
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.62
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Senescence-Activated NAD+ Depletion Rescue
Score: 0.60
Multi-Modal Stress Response Harmonization
Score: 0.60
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.59
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
Microbial Inflammasome Priming Prevention
Score: 0.58
PARP1 Inhibition Therapy
Score: 0.58
TREM2-Mediated Cholesterol Dysregulation in Microglial Senes
Score: 0.57
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli
Score: 0.57
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Synthetic Biology BBB Endothelial Cell Reprogramming
Score: 0.57
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.56
Smartphone-Detected Motor Variability Correction
Score: 0.56
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56
Adenosine-Astrocyte Metabolic Reset
Score: 0.56
Purinergic Signaling Polarization Control
Score: 0.55
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
Blood-Brain Barrier SPM Shuttle System
Score: 0.55
Circadian Clock-Autophagy Synchronization
Score: 0.55
Show 25 more
Related Analyses (30)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
Show 25 more
Related Experiments (23)
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Metal Ion Homeostasis Dysregulation in Alzheimer's Disease
validation · proposed · Score: 0.40
Show 18 more